PT-141 (Bremelanotide): A Melanocortin Receptor Agonist — Research Overview
PT-141 (Bremelanotide): A Melanocortin Receptor Agonist — Research Overview
PT-141, also known by its clinical development name Bremelanotide, is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is a synthetic melanocortin receptor agonist originally derived as a metabolite of Melanotan II during early pharmacological studies. Unlike its parent compound, PT-141 was found to have preferential activity at the melanocortin-4 receptor (MC4R) and reduced activity at MC1R (the receptor primarily responsible for melanogenesis), leading researchers to investigate it through a different mechanistic lens. PT-141 was developed by Palatin Technologies for research purposes.
Mechanism of Action
PT-141 functions as an agonist at melanocortin receptors, with preferential activity at MC4R and MC3R. The melanocortin system is a complex neuroendocrine signaling network with receptors distributed throughout the central nervous system, including the hypothalamus, limbic system, and brainstem.
MC4R, the primary target of interest in PT-141 research, is a G protein-coupled receptor expressed in hypothalamic nuclei that plays a role in multiple homeostatic functions. Activation of MC4R by PT-141 triggers downstream signaling cascades involving cAMP/PKA and intracellular calcium pathways (Wikberg & Mutulis, European Journal of Pharmacology, 2008).
The critical distinction between PT-141 and other melanocortin analogs is its mechanism of action: PT-141 acts centrally (in the brain) rather than peripherally. This central mechanism has been the focus of preclinical studies examining how melanocortin receptor activation in the CNS influences autonomic pathways and neuroendocrine responses (Diamond et al., International Journal of Impotence Research, 2004; PMID: 15085183).
Published Research
Melanocortin receptor pharmacology: Binding studies have characterized PT-141's affinity profile across the five melanocortin receptor subtypes (MC1R–MC5R). PT-141 demonstrates agonist activity primarily at MC3R and MC4R, with reduced affinity at MC1R compared to Melanotan II. This receptor selectivity profile distinguishes its biological effects from those of less selective melanocortin agonists (Hadley et al., Peptides, 2005; PMID: 15911067).
Central nervous system studies: In rodent models, PT-141 administration was associated with activation of hypothalamic neurons in regions expressing MC4R, as demonstrated by c-Fos immunohistochemistry. These studies established that PT-141's mechanism involves central melanocortin pathway activation rather than peripheral receptor stimulation (Diamond et al., International Journal of Impotence Research, 2004; PMID: 15085183).
Receptor selectivity: Comparative studies between PT-141 and its parent compound Melanotan II have examined how the structural modifications leading to PT-141 (loss of the N-terminal acyclic portion during metabolism) alter the receptor binding profile and downstream signaling patterns across the melanocortin receptor family.
Autonomic effects: In preclinical studies, PT-141 administration was observed to influence autonomic nervous system parameters, including cardiovascular measurements. Researchers documented transient effects on blood pressure that were attributed to central melanocortin receptor activation and subsequent autonomic pathway modulation.
Purity and Quality Considerations
PT-141 is a cyclic peptide with a lactam bridge, requiring specialized cyclization chemistry during synthesis. Researchers should verify that the cyclization is complete (no linear precursor contamination), confirm purity ≥98% by HPLC, and verify the correct molecular weight by mass spectrometry. The D-Phe residue and norleucine (Nle) substitution should be confirmed by the manufacturer's analytical data. Learn more about peptide purity testing and quality standards.
Available for Research
CALM Peptides offers research-grade PT-141 with third-party purity verification. Certificates of Analysis are available upon request. Browse our full catalog.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It has preferential activity at MC4R and MC3R and is studied in preclinical models for its effects on the central melanocortin system.
How does PT-141 differ from Melanotan II?
PT-141 was originally identified as a metabolite of Melanotan II. Structurally, it lacks the N-terminal acyclic portion of MT-II. This modification results in reduced MC1R activity (less melanogenesis-related effects) and a pharmacological profile more focused on MC4R-mediated central mechanisms.
What are melanocortin receptors?
Melanocortin receptors (MC1R–MC5R) are a family of G protein-coupled receptors that respond to melanocyte-stimulating hormones (MSH) and related peptides. They regulate diverse functions including pigmentation (MC1R), energy homeostasis (MC4R), and immune modulation (MC3R, MC5R).
What is the significance of PT-141's central mechanism?
PT-141 acts on melanocortin receptors in the central nervous system rather than on peripheral tissues. This central mechanism of action is the primary area of interest in preclinical research, as it involves hypothalamic neural circuits and downstream autonomic pathways.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. PT-141 is sold as a research chemical for laboratory use only. It is not intended for human consumption, and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.
For research use only. Not for human consumption.
Related Reading: What Are Peptides? · Melanotan II Research Overview · Quality & Purity Standards · Peptide Purity Testing
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.